Stratagene And Merck & Co., Inc. (MRK) Subsidiary, Rosetta Inpharmatics, Inc. (MRK), Enter Into Joint Development And License Agreement; Companies Will Develop RNA Purification System For Use In Molecular Diagnostics And Research Applications
8/14/2006 3:58:47 PM
Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostics products, announced today that it has entered into a joint development and license agreement with Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc., to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Nucleic acid purification allows researchers to separate RNA contained in biological samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.
comments powered by